Amniotic fluid stem cells: an ideal resource for therapeutic application in bone tissue engineering

Area of Science:

• Regenerative Medicine
• Stem Cell Biology
• Skeletal Tissue Engineering

Background:

• Skeletal diseases, including degenerative conditions and those secondary to trauma, infections, or tumors, are significant targets for regenerative medicine.
• Various stem cell sources, such as mesenchymal stem cells, embryonic stem cells (ESCs), and induced pluripotent stem cells (iPSCs), have demonstrated osteogenic potential for bone regeneration.
• Adult mesenchymal stem cells, embryonic stem cells (ESCs), and induced pluripotent stem cells (iPSCs) show significant osteogenic potential.

Purpose of the Study:

• To review the advantages of using amniotic fluid-derived stem cells (AFSCs) for treating skeletal diseases.
• To explore the application of AFSCs in conjunction with tissue engineering and biomaterials for skeletal regeneration.

Main Methods:

• This study is a narrative review analyzing the potential of AFSCs.
• The review focuses on the application of tissue engineering and biomaterials with AFSCs for skeletal disease treatment.

Main Results:

• Amniotic fluid-derived stem cells (AFSCs) possess high renewal capacity and can differentiate into multiple lineages.
• AFSCs exhibit low immunogenicity and have shown no tumor formation after transplantation in nude mice.

Conclusions:

• AFSCs are a promising stem cell source for regenerative medicine due to their differentiation capabilities and safety profile.
• The unique features of AFSCs make them an attractive model for developing novel treatments for skeletal diseases, particularly when combined with tissue engineering strategies.